Table 1.
Patient demographics and baseline characteristics
| Measure |
Olanzapine versus haloperidol |
Olanzapine versus risperidone |
Olanzapine versus ziprasidone |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Olanzapine (n = 211) | Haloperidol (n = 145) | Pvalue | Olanzapine (n = 159) | Risperidone (n = 158) | Pvalue | Olanzapine (n = 277) | Ziprasidone (n = 271) | Pvalue | |
| Age, years, mean (SD) | 38.6 (8.4) | 39.7 (8.6) | 0.20 | 38.4 (7.9) | 39.5 (8.3) | 0.23 | 40.1 (11.6) | 38.2 (12.1) | 0.07 |
| Age at onset, mean (SD) | 22.6 (6.9) | 22.0 (7.2) | 0.41 | 23.0 (7.0) | 23.3 (7.2) | 0.72 | 23.9 (8.3) | 22.8 (8.2) | 0.11 |
| Males, % | 72.0 | 71.0 | 0.90 | 72.3 | 70.2 | 0.71 | 65.0 | 63.5 | 0.72 |
| Racial/ethnic origin, n (%) | 0.27 | 0.31 | 0.77 | ||||||
| African | 62 (29.4) | 52 (35.9) | 43 (27.0) | 43 (27.2) | 78 (28.2) | 66 (24.4) | |||
| Caucasian | 121 (57.3) | 71 (49.0) | 95 (59.7) | 101 (63.9) | 115 (41.5) | 124 (45.8) | |||
| East Asian | 5 (2.4) | 2 (1.4) | 3 (1.9) | 2 (1.3) | 2 (0.7) | 3 (1.1) | |||
| Hispanic | 15 (7.1) | 11 (7.6) | 13 (8.2) | 6 (3.8) | 63 (22.7) | 61 (22.5) | |||
| South Asian | 2 (1.0) | 0 (0.0) | 2 (1.3) | 0 (0.0) | 1 (0.4) | 0 (0.0) | |||
| Other | 6 (2.8) | 9 (6.2) | 3 (1.9) | 6 (3.8) | 18 (6.5) | 17 (6.3) | |||
| Diagnosis, n (%) | 0.96 | 0.14 | – | ||||||
| Schizophrenia | 135 (64.0) | 94 (64.8) | 105 (66.0) | 117 (74.0) | 277 (100.0) | 271 (100.0) | |||
| Schizoaffective | 75 (35.6) | 50 (34.5) | 54 (34.0) | 41 (26.0) | 0 (0.0) | 0 (0.0) | |||
| Schizophreniform | 1 (0.5) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Baseline PANSS total, mean (SD) | 87.2 (16.5) | 88.5 (17.6) | 0.47 | 82.6 (13.1) | 84.2 (14.7) | 0.32 | 99.8 (19.1) | 102.0 (21.2) | 0.19 |
| Mean modal dose (mg/day), mean | 14.0 | 16.4 | – | 12.3 | 5.2 | – | 15.3 | 116.0 | – |
Abbreviations: PANSS, Positive and Negative Syndrome Scale; SD, standard deviation.